Evaluation of cell cycle arrest in estrogen responsive MCF-7 breast cancer cells: Pitfalls of the MTS assay

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  McGowan, Eileen M ^a,b   Alling, Nikki ^c   Jackson, Elise A ^b,d   Yagoub, Daniel ^a   Haass, Nikolas K ^b,d   Allen, John D ^b,d   Martinello Wilks, Rosetta ^a  

^a UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d CENTENARY INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYLTHIAZOL 2 YL) 5 (3 CARBOXYMETHOXYPHENYL) 2 (4 SULFOPHENYL) 2H TETRAZOLIUM; 5 ETHYNYLDEOXYURIDINE; ALEXA FLUOR; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DEOXYURIDINE DERIVATIVE; DNA; ESTROGEN; FINGOLIMOD; FLUORESCENT DYE; FULVESTRANT; SYBR GREEN; TETRAZOLE DERIVATIVE; UNCLASSIFIED DRUG; 3-(4,5-DIMETHYLTHIAZOL-2-YL)-5-(3-CARBOXYMETHOXYPHENYL)-2-(4-SULFOPHENYL)-2H-TETRAZOLIUM; 5-ETHYNYL-2'-DEOXYURIDINE; ANTINEOPLASTIC AGENT; DEOXYURIDINE; DRUG DERIVATIVE; ESTRADIOL; ISOPROPYL THIOGALACTOSIDE; PROPANEDIOL DERIVATIVE; SPHINGOSINE; TETRAZOLIUM; THIAZOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOMASS; BREAST CANCER; CANCER RESEARCH; CELL ASSAY; CELL COUNT; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL DEATH; CELL METABOLISM; CELL STRAIN MCF 7; CELL VIABILITY; CHEMICAL LABELING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DETERMINATION; DNA SYNTHESIS; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; FLUORESCENCE MICROSCOPY; HORMONE RESPONSE; IMAGE ANALYSIS; IN VITRO STUDY; MITOCHONDRIAL BIOMASS; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; MITOSIS INHIBITION; PROTEIN INDUCTION; BREAST TUMOR; CELL CYCLE; CELL PROLIFERATION; COLORIMETRY; CULTURE MEDIUM; DRUG DESIGN; DRUG EFFECT; HUMAN; METABOLISM; METHODOLOGY; MITOCHONDRION; PATHOLOGY; REPRODUCIBILITY; TUMOR CELL LINE;

ALEXA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL COUNT; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; COLORIMETRY; CULTURE MEDIA, SERUM-FREE; DEOXYURIDINE; DNA; DRUG DESIGN; ESTRADIOL; ESTROGENS; FLUORESCENT DYES; HUMANS; ISOPROPYL THIOGALACTOSIDE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; PROPYLENE GLYCOLS; REPRODUCIBILITY OF RESULTS; SPHINGOSINE; TETRAZOLIUM SALTS; THIAZOLES; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 79958049154     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020623     Document Type: Article

References (23)

1. Ali S, Coombes RC, (2002) Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2: 101-112.
2. Carroll JS, Prall OW, Musgrove EA, Sutherland RL, (2000) A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence. J Biol Chem 275: 38221-38229.
3. Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, et al. (2010) Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 9: 883-897.
4. Chun J, Hartung HP, (2010) Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 33: 91-101.
5. Sukocheva O, Wang L, Verrier E, Vadas MA, Xia P, (2009) Restoring endocrine response in breast cancer cells by inhibition of the sphingosine kinase-1 signaling pathway. Endocrinology 150: 4484-4492.
6. Nagahara Y, Ikekita M, Shinomiya T, (2000) Immunosuppressant FTY720 induces apoptosis by direct induction of permeability transition and release of cytochrome c from mitochondria. J Immunol 165: 3250-3259.
7. Shangary S, Wang S, (2009) Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 49: 223-241.
8. Clark PA, Llanos S, Peters G, (2002) Multiple interacting domains contribute to p14ARF mediated inhibition of MDM2. Oncogene 21: 4498-4507.
9. Liu W, Konduri SD, Bansal S, Nayak BK, Rajasekaran SA, et al. (2006) Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function. J Biol Chem 281: 9837-9840.
10. Saji S, Okumura N, Eguchi H, Nakashima S, Suzuki A, et al. (2001) MDM2 enhances the function of estrogen receptor alpha in human breast cancer cells. Biochem Biophys Res Commun 281: 259-265.
11. Duong V, Boulle N, Daujat S, Chauvet J, Bonnet S, et al. (2007) Differential regulation of estrogen receptor alpha turnover and transactivation by Mdm2 and stress-inducing agents. Cancer Res 67: 5513-5521.
12. Mosmann T, (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63.
13. Cory AH, Owen TC, Barltrop JA, Cory JG, (1991) Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun 3: 207-212.
14. Wang P, Henning SM, Heber D, (2010) Limitations of MTT and MTS-based assays for measurement of antiproliferative activity of green tea polyphenols. PLoS One 5: e10202.
15. Holland ML, Lau DT, Allen JD, Arnold JC, (2007) The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids. Br J Pharmacol 152: 815-824.
16. Allen JD, Jackson SC, Schinkel AH, (2002) A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance. Cancer Res 62: 2294-2299.
17. Stam RW, van den Heuvel-Eibrink MM, den Boer ML, Ebus ME, Janka-Schaub GE, et al. (2004) Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein. Leukemia 18: 78-83.
18. Dilda PJ, Don AS, Tanabe KM, Higgins VJ, Allen JD, et al. (2005) Mechanism of selectivity of an angiogenesis inhibitor from screening a genome-wide set of Saccharomyces cerevisiae deletion strains. J Natl Cancer Inst 97: 1539-1547.
19. Quelle DE, Zindy F, Ashmun RA, Sherr CJ, (1995) Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993-1000.
20. Howell A, Robertson JF, Quaresma Albano J, Aschermannova A, Mauriac L, et al. (2002) Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20: 3396-3403.
21. McGowan EM, Russell AJ, Boonyaratanakornkit V, Saunders DN, Lehrbach GM, et al. (2007) Progestins reinitiate cell cycle progression in antiestrogen-arrested breast cancer cells through the B-isoform of progesterone receptor. Cancer Res 67: 8942-8951.
22. McGowan EM, Clarke CL, (1999) Effect of overexpression of progesterone receptor A on endogenous progestin-sensitive endpoints in breast cancer cells. Mol Endocrinol 13: 1657-1671.
23. Salic A, Mitchison TJ, (2008) A chemical method for fast and sensitive detection of DNA synthesis in vivo. Proc Natl Acad Sci U S A 105: 2415-2420.